Search studies
50 studies found
OncoTrack
dc9c42f0-147a-11eb-b51f-8c8590c45a21
OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...
OncoTrack study
ELU-4-24D114-1
OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...
P2N ADPSOKO
e03298b0-91c8-11ed-97aa-acde48001122
PEI HUVEC-characterization study
ELU-4-4238C7-1
Within a broad characterization study, we analyzed activation, viability, cytokine secretion, and permeability of human umbilical vein endothelial cells (HUVECs) upon stimulation with different stimuli. In addition HUVEC-permeability was analyzed in a trans-well-based leakage assay upon stimulation in presence or absence of human peripheral blood mononuclear cells (PBMCs).
PRECISESADS: Cross Sectional Study & Inception Cohort
ELU-4-9E5405-1
The goal of this project is to use the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them of potential benefits in terms of the use of new therapeutic agents that are being developed for one disease but cannot be applied in another, due to current clinical classifications. We will investigate individuals with systemic lupus erythematosus ...
PRECISESADS: Cross Sectional Study - Lupus patients ...
ELU-4-32DBAB-1
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Cross Sectional Study
PSD-COVID19-OMICS
e6f87415-04f3-11ec-96d0-d0577bab103e
PSD COVID19 OMICS
Pfizer (NCT02958865)
ELU-4-B16B4B-1
The Pfizer UC dataset represents baseline, placebo and treatment (PF-06700841) subject and sample-level data extracted from a phase 2 study in moderate to severe ulcerative colitis.
